Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Saturn Oil & Gas Inc. Announces its First Development of Cardium Wells at Brazeau and Continued Successful Development (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News BioLineRx ADS Representing 15 Ord Shs BLRX

Healthcare Biotechnology
BioLine RX Ltd is an Israel-based clinical-stage biopharmaceutical company focused on oncology. The Company is commited into in-license novel compounds, develop them through clinical stages, and then partner with pharmaceutical companies for further clinical development andcommercialization. The Company is commited into two projects: Motixafortide (BL-8040), which is a cancer therapy platform ,... see more

Recent & Breaking News (NDAQ:BLRX)

BioLineRx Reports First Quarter 2013 Results

Business Wire May 7, 2013

BioLineRx's BL-7010, for the Treatment of Celiac, to be Presented at Two Leading Conferences

Business Wire May 2, 2013

BioLineRx to Report First Quarter 2013 Results on May 7, 2013

Business Wire April 30, 2013

BioLineRx Enrolls First Patient in Phase I/II Clinical Trial for BL-8020, an Oral, Interferon-Free Treatment for Hepatitis C

Business Wire April 29, 2013

Free Research Reports on APL, BLRX, INTC and OCZ Issued by the Bedford Report

Marketwired April 18, 2013

BioLineRx to Present at the 12th Annual Needham Healthcare Conference in New York on April 30, 2013

Business Wire April 18, 2013

BioLineRx Announces Positive Phase II Results for BL-7040, an Orally Available Treatment for Inflammatory Bowel Disease

Business Wire April 17, 2013

Oramed Pharmaceuticals Appoints New Chief Operating Officer and VP of Business Development

PR Newswire April 16, 2013

Free Research Reports on AEO, ARO, BLRX and FAST Issued by the Paragon Report

Marketwired April 11, 2013

BioLineRx Receives Regulatory Approval to Commence Phase II Clinical Trial for BL-8040, for Treatment of Leukemia

Business Wire April 10, 2013

Free Research Reports on BLRX, DCTH, WNR and XONE Issued by the Bedford Report

Marketwired April 8, 2013

HealthSouth Corp. Soars to New 52-wk High on Share Buying Plans

PR Newswire March 21, 2013

Free Research Reports on APC, BLRX, SPRD and TSL Issued by the Bedford Report

Marketwired March 21, 2013

BioLineRx Announces Results from Interim Analysis of Phase II/III CLARITY Trial of BL-1020 for Schizophrenia

Business Wire March 20, 2013

BioLineRx Receives Approval from French Regulatory Authorities to Commence a Phase I/II Clinical Trial for BL-8020, an Oral, Interferon-Free Treatment for Hepatitis C

Business Wire March 13, 2013

BioLineRx Reports Year End 2012 Financial Results

Business Wire March 12, 2013

BioLineRx's EDP-14, for Treatment of Severe and Persistent Asthma, to Enter the Company's Main Therapeutic Pipeline as BL-9010

Business Wire February 28, 2013

BioLineRx to Report Fourth Quarter and Year End 2012 Results on March 12, 2013

Business Wire February 26, 2013

Free Research Reports on AGNC, BLRX, LDK and MCP Issued by the Bedford Report

Marketwired February 19, 2013

BioLineRx Announces Closing of $8 Million Offering of American Depositary Shares

Business Wire February 13, 2013